The introduction of proapoptotic pharmacological agents such as the antiapoptotic protein Bcl-2 inhibitor VEN has revolutionized the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.